Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine candidate. The study showed strong immune responses in infants compared ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

(PFE) is running a late-stage trial to test a new pneumococcal vaccine in healthy infants. The official title describes a Phase 3, randomized, double-blind study that compares a multivalent ...

"Young children have the greatest burden of severe disease, so choosing the right vaccine to protect against the main serotypes circulating in the community is crucial." — Tony Walls, MD, Department ...

—Spanish investigators analyzed pneumococcal lineages among adults with invasive pneumococcal disease (IPD) and assessed how the emergence of nonvaccine serotypes has contributed to the burden of ...

OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected ...

More than 95% of children statewide had received 10 school-required vaccines as of October, including those against chickenpox, whooping cough, hepatitis B, measles and polio, among others.